Breast Cancer

Dalpiciclib plus fulvestrant has been clinically demonstrated to significantly improve progression-free survival and reduce the risk for disease progression or death.

Despite their frailty and comorbidities in the elderly patient population, palbociclib was proven to be a well-tolerated treatment in elderly patients with advanced, ER-positive, HER2-negative breast cancer.

A completion of local treatment and neoadjuvant or adjuvant chemotherapy results in significantly longer survival, free of invasive or distant disease than placebo in patients with high-risk, HER2-negative early breast cancer, with germline BRCA1 or BRCA2 pathogenic variants.

Earlier this year, the independent data monitoring committee concluded that the OlympiA trial crossed the superiority boundary for its primary end point of invasive disease-free survival and demonstrated a sustainable, clinically relevant treatment effect for olaparib versus placebo in patients with germline BRCA mutation–positive, high-risk, HER2-negative, early breast cancer.

Patients with HR-positive, HER2-negative metastatic breast cancer are more likely to have disease response to palbociclib plus letrozole versus letrozole alone, according to a real-world study. However, in real-world practice, there is less information on the tumor response of palbociclib plus an aromatase inhibitor versus an aromatase inhibitor alone.

Clinical studies have demonstrated that olaparib is clinically efficacious in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer in a setting closely resembling the real world.

A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology.

PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available.

Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer.

In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.